Newsroom

  • Category

  • By Date

  • Press Release

    12 February 26

    Aurobindo Pharma Targets 2029 as Turning Point for Its Biosimilars Business

    Aurobindo Pharma expects its biosimilars division to become a major growth driver, targeting 2029 as a key turning point with expansion across Europe, the US, and emerging global markets.

    Read more
  • Press Release

    19 September 25

    CuraTeQ Biologics announces positive Phase 3 study results for Denosumab biosimilar

    Read more
  • Press Release

    04 July 25

    CuraTeQ Biologics receives EC marketing authorization for Dazublys – Trastuzumab biosimilar

    Read more